Insider Trading Activity For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Shamim Ruff , SVP of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reportedly Sold 12,138 shares of the company’s stock at an average price of 42.97 for a total transaction amount of $521,569.86 SEC Form
Insider Trading History For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Analyst Ratings For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
These are 4 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Buy (Score: 2.85) with a consensus target price of $62.50 , a potential (45.26% upside)
Analyst Ratings History For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
- On 9/1/2015 Susquehanna Bancshares Inc Boost Price Target of rating Neutral with a price target of $33.00 to $36.00
- On 10/23/2015 Bank of America Corporation Initiated Coverage of rating Buy with a price target of $49.00
- On 11/8/2015 Roth Capital Reiterated Rating Buy with a price target of $50.00
- On 5/5/2016 Ladenburg Thalmann Financial Services Downgraded rating Market Perform to Underperform with a price target of $13.00 to $5.00
- On 9/20/2016 WBB Securities Reiterated Rating Strong-Buy with a price target of $40.00 to $60.00
- On 10/2/2016 William Blair Reiterated Rating Outperform with a price target of $88.00
- On 10/27/2016 Wedbush Reiterated Rating Outperform with a price target of $72.00
Recent Trading Activity for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Shares of Sarepta Therapeutics, Inc. closed the previous trading session at 43.59 up +0.18 0.41% with 7,600,116 shares trading hands.